1. Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead
- Author
-
Wei-liang Qi, Yu-xiang Wang, Hui-yu Li, and Ling-hua Meng
- Subjects
Drug ,business.industry ,Colorectal cancer ,media_common.quotation_subject ,Locally advanced ,Cancer ,Cell Biology ,Drug resistance ,medicine.disease_cause ,medicine.disease ,Biochemistry ,Clinical trial ,Cancer research ,Medicine ,In patient ,KRAS ,business ,Molecular Biology ,Genetics (clinical) ,media_common - Abstract
KRAS is one of the most commonly mutated oncogenes in cancers and therapeutics directly targeting the KRas have been challenging. Among the different known mutants, KRasG12C has been proved to be successfully targeted recently. Several covalent inhibitors selectively targeting KRasG12C have shown promising efficacy against cancers harboring KRASG12C mutation in clinical trials and AMG510 (sotorasib) has been approved for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer. However, the overall responsive rate of KRasG12C inhibitors was around 50% in patients with non-small cell lung cancer and the efficacy in patients with colorectal cancer or appendiceal cancer appears to be less desirable. It is of great importance to discover biomarkers to distinguish patients who are likely benefitted. Moreover, adaptive resistance would occur inevitably with the persistent administration like other molecularly targeted therapies. Several combinatorial regimens have been studied in an effort to potentiate the efficacy of KRasG12C inhibitors in preclinical settings. This review summarized the recent progress of covalent KRasG12C inhibitors with a focus on identifying biomarkers to predict or monitor the efficacy and proposing rational drug combinations based on elucidation of the mechanisms of drug resistance.
- Published
- 2023